BIOMAT Database Logo BIOMAT Database Logo

New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. 2007

Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
1Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.

A regimen of busulfan and cyclophosphamide (BuCy2) is regarded as the standard myeloablative regimen for SCT. This study evaluated the hypothesis that fludarabine can replace cyclophosphamide for myeloablative allogeneic SCT. Ninety-five patients underwent allogeneic SCT from HLA-identical donors, following BuCy2 (n=55) or busulfan+fludarabine (BF, n=40). The efficacy of fludarabine compared to cyclophosphamide was retrospectively evaluated. The BF group exhibited a shorter duration until engraftment (P=0.001), lower incidence of acute and chronic GVHD (P<0.001 and P=0.003, respectively), and non-relapse mortality (NRM) (P=0.039). Furthermore, the event-free survival and overall survival were significantly higher for the BF group compared to the BuCy2 group (P=0.004 and 0.002, respectively). After adjusting for age, the risk status of disease, GVHD prophylaxis and donor type, the BF regimen was found to be an independent favorable risk factor for event-free survival (hazard ratio (HR), 0.181; 95% confidence interval, 0.045-0.720; P=0.016) and overall survival (HR, 0.168; 0.035-0.807; P=0.026). The replacement of cyclophosphamide with fludarabine for myeloablative conditioning seems to be more effective in terms of short-term NRM, and GVHD compared to BuCy2 regimen in allogeneic transplantation.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002066 Busulfan An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. Busulphan,Busulfan Wellcome,Busulfex,Glyzophrol,Myelosan,Mylecytan,Myleran,Myléran,n-Butane-1,3-di(methylsulfonate),Wellcome, Busulfan
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
July 2007, Bone marrow transplantation,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients.
April 2016, Molecular and clinical oncology,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
September 2001, Haematologica,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.
October 2010, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
August 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
August 2019, Bone marrow transplantation,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
December 2008, Pediatric transplantation,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.
December 2023, Transplantation and cellular therapy,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
January 2004, Blood,
Y S Chae, and S K Sohn, and J G Kim, and Y Y Cho, and J H Moon, and H J Shin, and J S Chung, and G J Cho, and D H Yang, and J-J Lee, and Y-K Kim, and H-J Kim
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
August 2003, Blood,
Copied contents to your clipboard!